LGT Fund Management Co Ltd. Raises Holdings in Eli Lilly and Company $LLY

LGT Fund Management Co Ltd. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 167.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,307 shares of the company’s stock after purchasing an additional 42,767 shares during the period. Eli Lilly and Company makes up about 2.7% of LGT Fund Management Co Ltd.’s holdings, making the stock its 8th biggest position. LGT Fund Management Co Ltd.’s holdings in Eli Lilly and Company were worth $62,827,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $25,000. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC increased its stake in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the last quarter. Basso Capital Management L.P. bought a new stake in Eli Lilly and Company during the fourth quarter worth $30,000. Finally, Maseco LLP raised its stake in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on LLY shares. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, July 1st. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Finally, Rothschild & Co Redburn raised their price objective on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,263.41.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,189.06 on Monday. The stock has a market cap of $1.12 trillion, a price-to-earnings ratio of 42.24, a PEG ratio of 1.47 and a beta of 0.51. The stock’s 50 day simple moving average is $1,098.66 and its two-hundred day simple moving average is $1,033.22. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 35.81 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and kept a buy rating, signaling confidence that the company still has meaningful upside after its recent run. Benzinga article
• Positive Sentiment: Lilly announced that its Phase 2 neuropathic pain trial reached completion, adding another potentially valuable pipeline asset beyond its blockbuster GLP-1 franchise. TipRanks article
• Positive Sentiment: News flow highlighting record GLP-1 adoption and accelerating sales remains supportive, since Lilly’s obesity and diabetes drugs continue to be the main driver of earnings momentum. Motley Fool article
• Positive Sentiment: Additional analyst commentary has been upbeat, with other firms also lifting targets and framing Lilly as one of the strongest growth names in healthcare. TheStreet article
• Neutral Sentiment: Institutional buying and “best mutual funds” lists suggest Lilly remains a favored large-cap healthcare holding, but this is more a sentiment indicator than a direct catalyst. Yahoo Finance article
• Negative Sentiment: Tampa General’s lawsuit over allegedly pulled 340B discounts adds legal and reimbursement risk, which could create some investor caution around Lilly’s pricing and hospital-channel relationships. Healthcare Finance News article

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.